If you don't record it, you will be punished for producing counterfeit drugs. Shandong introduced the filing policy of traditional Chinese medicine preparations. What is the significance of this move?

This move can regulate the drug market.

Generally speaking, the punishment of not filing fake drugs and the filing policy of traditional Chinese medicine preparations are all aimed at regulating the pharmaceutical market. These two policies make drug production under the strict supervision of Shandong pharmaceutical department. Specifically, these policies in Shandong have these meanings: First, standardize the market and put an end to the production of counterfeit drugs. Secondly, standardize industry rules, standardize drug production, and finally strengthen supervision over drug production. These will be explained in detail below:

First, Shandong's two drug production policies can first standardize the drug market and put an end to the production of counterfeit drugs: because if the production is not filed, it will be punished as counterfeit drugs, which means that the possibility of producing counterfeit drugs is completely blocked. Because those fake drug manufacturers will definitely not admit that they produce fake drugs. They are all secretly produced without filing. It can be said that the vast majority of counterfeit drugs on the market are produced without filing. Therefore, unregistered production is the hardest hit area for counterfeit drug production. The promulgation of these two regulations in Shandong completely put an end to the situation of unregistered production, thus basically destroying the main way of counterfeit drug production. Then, through the introduction of laws and policies for preparation filing, the drug market was further standardized, so the drug market was standardized.

Second, these two drug production policies in Shandong can standardize drug production: for drug production, especially the production of proprietary Chinese medicines, there has always been a problem of irregular production, because the ingredients of proprietary Chinese medicines are all Chinese medicines, and the ingredients of different pharmaceutical factories are different. Some may have more ingredients, while others may have less ingredients. With the filing policy of traditional Chinese medicine preparations, it is equivalent to unifying the production of proprietary Chinese medicines and forming standardization.

Third, these two drug production policies in Shandong can strengthen the supervision of drug production: because in order to thoroughly implement these two policies, the relevant departments in Shandong will certainly strengthen supervision and production supervision. Therefore, better drugs can be produced.